Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 276

1.

Estimating Exposome Score for Schizophrenia Using Predictive Modeling Approach in Two Independent Samples: The Results From the EUGEI Study.

Pries LK, Lage-Castellanos A, Delespaul P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akdede B, Binbay T, Altinyazar V, Yalinçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran EŞ, Kaymak SU, Mihaljevic MM, Petrovic SA, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşoğlu C, Ucok A, Alptekin K, Saka MC; Genetic Risk and Outcome of Psychosis (GROUP) investigators , Arango C, O'Donovan M, Rutten BPF, van Os J, Guloksuz S.

Schizophr Bull. 2019 Sep 11;45(5):960-965. doi: 10.1093/schbul/sbz054.

PMID:
31508804
2.

A polygenic resilience score moderates the genetic risk for schizophrenia.

Hess JL, Tylee DS, Mattheisen M; Schizophrenia Working Group of the Psychiatric Genomics Consortium; Lundbeck Foundation Initiative for Integrative Psychiatric Research (iPSYCH), Børglum AD, Als TD, Grove J, Werge T, Mortensen PB, Mors O, Nordentoft M, Hougaard DM, Byberg-Grauholm J, Bækvad-Hansen M, Greenwood TA, Tsuang MT, Curtis D, Steinberg S, Sigurdsson E, Stefánsson H, Stefánsson K, Edenberg HJ, Holmans P, Faraone SV, Glatt SJ.

Mol Psychiatry. 2019 Sep 6. doi: 10.1038/s41380-019-0463-8. [Epub ahead of print]

PMID:
31492941
3.

Visual hallucinations in psychosis.

van Ommen MM, van Laar T, Cornelissen FW, Bruggeman R.

Psychiatry Res. 2019 Oct;280:112517. doi: 10.1016/j.psychres.2019.112517. Epub 2019 Aug 10.

PMID:
31446216
4.

Insights of Patients and Clinicians on the Promise of the Experience Sampling Method for Psychiatric Care.

Bos FM, Snippe E, Bruggeman R, Wichers M, van der Krieke L.

Psychiatr Serv. 2019 Aug 22:appips201900050. doi: 10.1176/appi.ps.201900050. [Epub ahead of print]

PMID:
31434558
5.

Vitamin D concentration and psychotic disorder: associations with disease status, clinical variables and urbanicity.

van der Leeuw C, de Witte LD, Stellinga A, van der Ley C, Bruggeman R, Kahn RS, van Os J, Marcelis M; for G.R.O.U.P.

Psychol Med. 2019 Jul 22:1-7. doi: 10.1017/S0033291719001739. [Epub ahead of print]

PMID:
31327333
6.

"Please tell me what happened": A descriptive study on prevalence, disclosure and characteristics of victimization in people with a psychotic disorder.

de Vries B, Pijnenborg GHM, van der Stouwe ECD, Visser E, de Jong S; Pharmaco therapy and outcome survey (PHAMOUS)-investigators, Bartels-Velthuis AA, Bruggeman R, Castelein S, Jörg F, Veling W, Aleman A, van Busschbach JT.

PLoS One. 2019 Jul 18;14(7):e0219056. doi: 10.1371/journal.pone.0219056. eCollection 2019.

7.

Publisher Correction: Gene expression imputation across multiple brain regions provides insights into schizophrenia risk.

Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, Rajagopal VM, Als TD, T Nguyen H, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S; CommonMind Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; iPSYCH-GEMS Schizophrenia Working Group, Demontis D, Børglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA.

Nat Genet. 2019 Jun;51(6):1068. doi: 10.1038/s41588-019-0435-6.

8.

Examining the independent and joint effects of molecular genetic liability and environmental exposures in schizophrenia: results from the EUGEI study.

Guloksuz S, Pries LK, Delespaul P, Kenis G, Luykx JJ, Lin BD, Richards AL, Akdede B, Binbay T, Altınyazar V, Yalınçetin B, Gümüş-Akay G, Cihan B, Soygür H, Ulaş H, Cankurtaran E, Kaymak SU, Mihaljevic MM, Petrovic SA, Mirjanic T, Bernardo M, Cabrera B, Bobes J, Saiz PA, García-Portilla MP, Sanjuan J, Aguilar EJ, Santos JL, Jiménez-López E, Arrojo M, Carracedo A, López G, González-Peñas J, Parellada M, Maric NP, Atbaşog Lu C, Ucok A, Alptekin K, Saka MC; Genetic Risk and Outcome of Psychosis (GROUP) investigators, Arango C, O'Donovan M, Rutten BPF, van Os J.

World Psychiatry. 2019 Jun;18(2):173-182. doi: 10.1002/wps.20629.

9.

Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling.

van Rooijen G, van Rooijen M, Maat A, Vermeulen JM, Meijer CJ, Ruhé HG, de Haan L; GROUP investigators; Genetic Risk and Outcome of Psychosis investigators:, Alizadeh BZ, Bartels-Velthuis AA, van Beveren NJ, Bruggeman R, Cahn W, Delespaul P, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Amelsvoort T, van Haren NE, van Os J, van Winkel R.

Schizophr Res. 2019 Jun;208:82-89. doi: 10.1016/j.schres.2019.04.011. Epub 2019 Apr 29.

PMID:
31047723
10.

Gene expression imputation across multiple brain regions provides insights into schizophrenia risk.

Huckins LM, Dobbyn A, Ruderfer DM, Hoffman G, Wang W, Pardiñas AF, Rajagopal VM, Als TD, T Nguyen H, Girdhar K, Boocock J, Roussos P, Fromer M, Kramer R, Domenici E, Gamazon ER, Purcell S; CommonMind Consortium; Schizophrenia Working Group of the Psychiatric Genomics Consortium; iPSYCH-GEMS Schizophrenia Working Group, Demontis D, Børglum AD, Walters JTR, O'Donovan MC, Sullivan P, Owen MJ, Devlin B, Sieberts SK, Cox NJ, Im HK, Sklar P, Stahl EA.

Nat Genet. 2019 Apr;51(4):659-674. doi: 10.1038/s41588-019-0364-4. Epub 2019 Mar 25. Erratum in: Nat Genet. 2019 Jun;51(6):1068.

PMID:
30911161
11.

Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia.

Harold D, Connolly S, Riley BP, Kendler KS, McCarthy SE, McCombie WR, Richards A, Owen MJ, O'Donovan MC, Walters J; Wellcome Trust Case Control Consortium 2; Schizophrenia Working Group of the Psychiatric Genomics Consortium, Donohoe G, Gill M, Corvin A, Morris DW.

Am J Med Genet B Neuropsychiatr Genet. 2019 Apr;180(3):223-231. doi: 10.1002/ajmg.b.32716. Epub 2019 Feb 23.

PMID:
30801977
12.

[Decision aid for the treatment of psychotic illness: development of TReatment E-AssisT (TREAT)].

Roebroek LO, Bruins J, Knegtering H, Bruggeman R, Delespaul PH, Castelein S.

Tijdschr Psychiatr. 2019;61(2):92-96. Dutch.

13.

Design and methods of the 'monitoring outcomes of psychiatric pharmacotherapy' (MOPHAR) monitoring program - a study protocol.

Simoons M, Ruhé HG, van Roon EN, Schoevers RA, Bruggeman R, Cath DC, Muis D, Arends J, Doornbos B, Mulder H.

BMC Health Serv Res. 2019 Feb 14;19(1):125. doi: 10.1186/s12913-019-3951-2.

14.

Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study.

Swets M, van Dijk FA, Schirmbeck F, Peen J, de Haan L, Alizadeh BZ, van Amelsvoort T, Bartels-Velthuis AA, van Beveren NJ, Bruggeman R, Cahn W, Delespaul P, Luykx JJ, Myin-Germeys I, Kahn RS, Simons CJP, van Haren NE, van Os J, van Winkel R.

Psychiatry Res. 2019 Jan;271:421-427. doi: 10.1016/j.psychres.2018.11.071. Epub 2018 Dec 3.

PMID:
30537664
15.

Childhood adversities and psychotic symptoms: The potential mediating or moderating role of neurocognition and social cognition.

Mansueto G, Schruers K, Cosci F, van Os J; GROUP Investigators.

Schizophr Res. 2019 Apr;206:183-193. doi: 10.1016/j.schres.2018.11.028. Epub 2018 Dec 5.

PMID:
30527930
16.

Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study.

Vermeulen J, Schirmbeck F, Blankers M, van Tricht M, van den Brink W, de Haan L; Genetic Risk and Outcome of Psychosis (GROUP) investigators.

Lancet Psychiatry. 2019 Jan;6(1):25-34. doi: 10.1016/S2215-0366(18)30424-3. Epub 2018 Dec 5. Erratum in: Lancet Psychiatry. 2019 Feb;6(2):e5.

PMID:
30527763
17.

Metabolic Syndrome at an Outpatient Clinic for Bipolar Disorders: A Case for Systematic Somatic Monitoring.

Simoons M, Mulder H, Doornbos B, Raats PCC, Bruggeman R, Cath DC, Schoevers RA, Ruhé HG, van Roon EN.

Psychiatr Serv. 2019 Feb 1;70(2):143-146. doi: 10.1176/appi.ps.201800121. Epub 2018 Dec 10.

PMID:
30526344
18.

Functional recovery of individuals with serious mental illnesses: Development and testing of a new short instrument for routine outcome monitoring.

Swildens WE, Visser E, Bähler M, Bruggeman R, Delespaul P, van der Gaag M, de Haan L, Keet R, Nijssen Y, van Os J, Pijnenborg GM, Slooff C, de Vos A, van Weeghel J, Wunderink L, Mulder CL, Wiersma D.

Psychiatr Rehabil J. 2018 Dec;41(4):341-350. doi: 10.1037/prj0000320.

PMID:
30507243
19.

Targeted Sequencing of 10,198 Samples Confirms Abnormalities in Neuronal Activity and Implicates Voltage-Gated Sodium Channels in Schizophrenia Pathogenesis.

Rees E, Carrera N, Morgan J, Hambridge K, Escott-Price V, Pocklington AJ, Richards AL, Pardiñas AF; GROUP Investigators, McDonald C, Donohoe G, Morris DW, Kenny E, Kelleher E, Gill M, Corvin A, Kirov G, Walters JTR, Holmans P, Owen MJ, O'Donovan MC.

Biol Psychiatry. 2019 Apr 1;85(7):554-562. doi: 10.1016/j.biopsych.2018.08.022. Epub 2018 Oct 1.

20.

Corrigendum to "Long-term course of negative symptom subdomains and relationship with outcome in patients with a psychotic disorder" [Schizophr. Res. 193 (2018) 173-181].

Stiekema APM, Islam MA, Liemburg EJ, Castelein S, van den Heuvel ER, van Weeghel J, Aleman A, Bruggeman R, van der Meer L; GROUP investigators, Alizadeh BZ, Bartels-Velthuis AA, van Beveren NJ, Bruggeman R, Cahn W, de Haan L, Delespaul P, Meijer CJ, Myin-Germeys I, Kahn RS, Schirmbeck F, Simons CJP, van Haren NEM, van Os J, van Winkel R.

Schizophr Res. 2019 Feb;204:462-463. doi: 10.1016/j.schres.2018.10.003. Epub 2018 Oct 9. No abstract available.

PMID:
30314649

Supplemental Content

Loading ...
Support Center